Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours

#1711

Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.

Aim(s): The aim of our study was to investigate if there is a survival benefit from the combined therapy.

Materials and methods: The investigation included 225 patients with progressive gastroenenteropancreatic neuroendocrine tumours. 98 of the patients received a combined therapy with PRRT and SSA, 127 patients had a PRRT monotherapy. For the survival analysis the minimal follow-up was 6 months.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Yordanova A

Authors: Yordanova A, Wicharz M, Gonzalez-Carmona M, Strassburg C, Mayer K,

Keywords: PRRT, SSA, combined therapy, survival,